Answers are grounded in this paper and cite their sources.
Obesity remains a major public health challenge in both high income and developing regions of the world. Most recently, the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss has shifted public interest in some countries away from traditional strategies for obesity management and toward strategies centered on these pharmaceutical agents. However, despite brisk uptake, their overall penetration among obese populations remains low, discontinuation rates related to side effects and costs are high, and many patients prefer nonpharmacologic approaches to weight loss.
No takes yet. Share an insight, caveat, or question.
Joseph A. Ladapo (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: